TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12182381

Group type: EXPERIMENTAL
Intervention: M-M-R II and VARIVAX given concomitantly at separate sites (Group A)
Number of subjects: 603

Group type: COMPARATOR
Intervention: M-M-R II and VARIVAX administered 6 weeks apart (Group B)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 603
Study: 10622297

Group type: EXPERIMENTAL
Intervention: Formula with LCPUFAs
Number of subjects: 447

Group type: COMPARATOR
Intervention: Formula without LCPUFAs
Number of subjects: 447

Group type: COMPARATOR
Intervention: Breastfed reference group
Number of subjects: 447
Study: 8575573

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 micrograms b.i.d. for 3 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 3 months
Number of subjects: 27
Study: 1827588

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 10

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 10
Study: 375881

Group type: EXPERIMENTAL
Intervention: Penicillamine treatment (250 mg, 3 capsules per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (lactose, 3 capsules per day)
Number of subjects: 11
Study: 28633675

Group type: EXPERIMENTAL
Intervention: Jiao's scalp acupuncture combined with conventional rehabilitation treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment
Number of subjects: 108
Study: 26426042

Group type: EXPERIMENTAL
Intervention: 0.5 mg intramuscular phylloquinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg intramuscular phylloquinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous phylloquinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolus dose of phylloquinone at birth
Number of subjects: 0
Study: 23110811

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CT) with epirubicin 120 mg/m² and ifosfamide 9 g/m² followed by two postoperative cycles
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CT) with radiotherapy (RT)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Combined preoperative CT-RT in patients with positive surgical margins
Number of subjects: 252
Study: 20963831

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (112 mg, twice daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 19197779

Group type: EXPERIMENTAL
Intervention: Web-based course on cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype module of the Web-based course
Number of subjects: 0
Study: 16961166

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 70
Study: 15589109

Group type: EXPERIMENTAL
Intervention: Single oral dose of galantamine (GAL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline (no galantamine)
Number of subjects: 28
Study: 11064501

Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy (two nucleoside reverse transcriptase inhibitors (NRTIs) plus one protease inhibitor)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Double therapy (two NRTIs)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Double therapy and Triple therapy
Number of subjects: 94
Study: 9308583

Group type: EXPERIMENTAL
Intervention: Surgical management (n = 56)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Endovascular management (n = 59)
Number of subjects: 115
Study: 8144850

Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in early follicular phase)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in late luteal phase)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant on 3rd and 17th day from onset of menses)
Number of subjects: 18
Study: 3530442

Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study: 29976078

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg multi-strain probiotic (MS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg single-strain probiotic (SS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg of both probiotics (MS+ SS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.5 g/kg oxytetracycline antibiotic (OX)
Number of subjects: 300

Group type: COMPARATOR
Intervention: basal diet (negative control)
Number of subjects: 300
Study: 27855663

Group type: EXPERIMENTAL
Intervention: Jom Mama intervention
Number of subjects: 0
Study: 24123482

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 209
Study: 22631214

Group type: EXPERIMENTAL
Intervention: Nut-enriched diet (walnuts, hazelnuts, almonds) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nut-free control diet
Number of subjects: 0
Study: 20980654

Group type: EXPERIMENTAL
Intervention: Aleurone-rich cereal products (27 g/d aleurone)
Number of subjects: 79
Study: 16442463

Group type: EXPERIMENTAL
Intervention: Early psychosocial intervention starting within 4 months after surgery
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed psychosocial intervention starting at least 3 months later
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both early and delayed interventions
Number of subjects: 67
Study: 15304189

Group type: EXPERIMENTAL
Intervention: 5% ascorbic acid cream
Number of subjects: 16

Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 16
Study: 12789117

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 120
Study: 9234823

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8300

Group type: COMPARATOR
Intervention: Atenolol (Control)
Number of subjects: 8300
Study: 8507449

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (100 mg/day, orally for 1 month)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 15
Study: 3431029

Group type: EXPERIMENTAL
Intervention: Polyenylphosphatidylcholine (10 g per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Safflower oil (7 g per day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 8
Study: 28570305

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) distraction therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: No Immersive Virtual Reality (no IVR)
Number of subjects: 18
Study: 26581246

Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV) plus best supportive care (BSC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 80
Study: 24274798

Group type: EXPERIMENTAL
Intervention: Expressive Helping (EH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer Helping (PH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expressive Writing (EW)
Number of subjects: 0
Study: 22362846

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 20378181

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation, 10 sessions, 10,000 stimuli over left dorsolateral prefrontal cortex at 110% of motor threshold)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 35
Study: 17909750

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15991021

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study: 12738499

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 48
Study: 11710653

Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg per day of G115)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9024299

Group type: EXPERIMENTAL
Intervention: Oral calcium phosphate supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7984562

Group type: EXPERIMENTAL
Intervention: Erythrocytic diagnosticum with BCG tuberculin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specially designed diagnostic preparations made of TB and BCG vaccine strain tuberculin
Number of subjects: 0
Study: 2880497

Group type: EXPERIMENTAL
Intervention: Beta-blocking drugs
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no beta-blocking drugs)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (baseline recording)
Number of subjects: 88
Study: 29247383

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg
Number of subjects: 466

Group type: COMPARATOR
Intervention: Platinum-based doublet chemotherapy
Number of subjects: 466
Study: 27938361

Group type: EXPERIMENTAL
Intervention: Combination of spa therapy, exercise, and self-management workshops for 6 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25535778

Group type: EXPERIMENTAL
Intervention: Sealing composite restorations
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Positive control (composites with Alfa values for marginal adaptation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups (including sealing and no treatment)
Number of subjects: 20
Study: 23103364

Group type: EXPERIMENTAL
Intervention: Overall radiotherapy (RT)
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: Radiotherapy after conservative breast surgery (PBRT)
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (PRT)
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: PMRT in stage III disease
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: PBRT in node-positive stage II disease
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: PBRT in patients treated by breast conservative surgery
Number of subjects: 3732
Study: 21431625

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 203
Study: 17622255

Group type: EXPERIMENTAL
Intervention: 15 mg Zn/day
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/day
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 17200730

Group type: EXPERIMENTAL
Intervention: Various drugs including 5‐Methyltetrahydrofolate, (R)‐flurbiprofen, Ad5CMV‐p53, adalimumab, alefacept, alemtuzumab, Alequel, alicaforsen sodium, almotriptan, anakinra, aprepitant, aripiprazole, armodafinil, Bevacizumab, bortezomib, bosentan, Canfosfamide hydrochloride, ciclesonide, clofarabine, Cypher, Darbepoetin alfa, diclofenac potassium, drotrecogin alfa (activated), duloxetine hydrochloride, Eel calcitonin, eletriptan, eplerenone, everolimus, ezetimibe, Frovatriptan, Gefitinib, γ‐hydroxybutyrate sodium, HKI‐272, HYB‐165, Ibutamoren mesylate, imatinib mesylate, interleukin‐21, ixabepilone, KRN‐951, L‐Arginine hydrochloride, levodopal carbidopa/entacapone, Micafungin sodium, motexafin gadolinium, mycophenolic acid sodium salt, Nesiritide, Peginterferon alfa‐2a, pitavastatin calcium, pralatrexate, pregabalin, pVAX/L523S‐Ad.L523S, Rasagiline mesylate, recombinant human nerve growth factor, regadenoson, rF‐PSA, rimonabant, rizatriptan, rofecoxib, rosuvastatin calcium, rV‐B7.1, rV‐PSA, Sipuleucel‐T, sirolimus‐eluting stent, solifenacin succinate, sorafenib, sunitinib malate, Talactoferrin alfa, Taxus, tegaserod maleate, teriparatide, tipifarnib, Valdecoxib, vandetanib, vatalanib succinate, WT1‐peptide vaccine, Xaliproden hydrochloride
Number of subjects: 0
Study: 13129416

Group type: EXPERIMENTAL
Intervention: Oral tegafur plus uracil (UFT) plus folinic acid
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Intravenous fluorouracil (FU) plus oral folinic acid (leucovorin)
Number of subjects: 1396
Study: 10632648

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. (RBCCT group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. (RBCCA group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: RBCCT group
Number of subjects: 80
Study: 8619505

Group type: EXPERIMENTAL
Intervention: Inhaled exposure to carbon monoxide at sea level
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled exposure to carbon monoxide at high altitude
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled exposure to clean air at sea level
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled exposure to clean air at high altitude
Number of subjects: 10
Study: 1534547

Group type: EXPERIMENTAL
Intervention: Tetracycline/metronidazole (n = 67)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Augmentin (n = 22)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/metronidazole (n = 21)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tetracycline/metronidazole with balneotherapy (n = 34)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no balneotherapy, n = 33)
Number of subjects: 110
Study: 6696214

Group type: EXPERIMENTAL
Intervention: Enflurane 1% in air
Number of subjects: 20

Group type: COMPARATOR
Intervention: Entonox (50% nitrous oxide in oxygen)
Number of subjects: 20
Study: 30456568

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No bone void filler (group B)
Number of subjects: 40
Study: 28855223

Group type: EXPERIMENTAL
Intervention: DASH diet (low in fat and high in protein, low-fat dairy, and fruits and vegetables) with high sodium (150 nmol or 3450 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DASH diet with medium sodium (100 nmol or 2300 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium (50 nmol or 1150 mg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 119
Study: 25935787

Group type: EXPERIMENTAL
Intervention: 0.3‐mg intravitreal ranibizumab injection therapy
Number of subjects: 0
Study: 24284115

Group type: EXPERIMENTAL
Intervention: 5% ALA gel applied topically for 1h incubation followed by LED light irradiation at 633 nm, 96-120 J/cm² for 3-4 sessions
Number of subjects: 397
Study: 21885731

Group type: EXPERIMENTAL
Intervention: High-fat/low-fiber diet
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Low-fat/high-fiber diet
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (enterotype identity)
Number of subjects: 98
Study: 19074355

Group type: EXPERIMENTAL
Intervention: Massage therapy (4 weekly sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Quiet-time control (4 weekly sessions)
Number of subjects: 23
Study: 16917914

Group type: EXPERIMENTAL
Intervention: Fibrinogen fragments (FF) isolated from uremic plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uremic plasma before HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uremic plasma after HD
Number of subjects: 0
Study: 14743852

Group type: EXPERIMENTAL
Intervention: Intermittent infusion of intravenous inotropes
Number of subjects: 73
Study: 11319593

Group type: COMPARATOR
Intervention: No VOD prophylaxis
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Heparin (Hep)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Heparin + Prostaglandin E1 (Hep + PGE1)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 462
Study: 9345174

Group type: COMPARATOR
Intervention: Control (alphabetical list of drugs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Limited support (list of preferred drugs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full support (the same list with explanations available for suggestions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Limited support
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full support
Number of subjects: 50
Study: 8084119

Group type: EXPERIMENTAL
Intervention: Erinit and allopurinol in conventional therapeutical doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Erinit
Number of subjects: 60
Study: 3318977

Group type: EXPERIMENTAL
Intervention: Low-level ultrasound
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30732199

Group type: EXPERIMENTAL
Intervention: Jia Wei Niu Bang Zi granule (NBZG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27306372

Group type: EXPERIMENTAL
Intervention: 0.25 mg roflumilast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.375 mg roflumilast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 mg roflumilast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple doses of 0.375 mg roflumilast
Number of subjects: 36

Group type: COMPARATOR
Intervention: Food effect on roflumilast
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gender effect on roflumilast and roflumilast N-oxide
Number of subjects: 36
Study: 26474518

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (150 mg once daily)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Bevacizumab (7.5 mg/kg every 3 weeks)
Number of subjects: 700
Study: 23011122

Group type: EXPERIMENTAL
Intervention: Split-belt treadmill walking
Number of subjects: 15

Group type: COMPARATOR
Intervention: Slow treadmill walking
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fast treadmill walking
Number of subjects: 15
Study: 21609207

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Vildagliptin 400 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 101

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 101
Study: 19332727

Group type: COMPARATOR
Intervention: Adjuvant doxorubicin (75 mg/m(2)) followed by CMF
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Adjuvant paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)), followed by CMF
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)) followed by CMF followed by surgery
Number of subjects: 1355
Study: 16460241

Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap (SCPF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 17
Study: 15288707

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg orally at 2300 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (14 subjects; 11 female, 3 male; mean age 15.7 ± 2.0 years)
Number of subjects: 14
Study: 11814087

Group type: EXPERIMENTAL
Intervention: Atrial pacing (AAI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ventricular pacing (VVI)
Number of subjects: 74
Study: 9801900

Group type: EXPERIMENTAL
Intervention: BCG vaccine (batch 1)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: BCG vaccine (batch 2)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 816
Study: 7620271

Group type: EXPERIMENTAL
Intervention: Asahi PAN 06 hollow fibre dialyser
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hospal AN69HF flat plate dialyser
Number of subjects: 7
Study: 2559242

Group type: EXPERIMENTAL
Intervention: Continental breakfast (low fibre, low protein, high fat)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk (low fat, high protein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: English breakfast (high fibre, high protein)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continental breakfast
Number of subjects: 32

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Test meals in closed-loop experiments
Number of subjects: 32
Study: 336078

Group type: COMPARATOR
Intervention: Bellergal (combination of belladonna alkaloids, ergotamine tartrate, and phenobarbitone), administered three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30885389

Group type: EXPERIMENTAL
Intervention: Recall + EM (32 intervals of 24s)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Recall only (32 intervals of 24s)
Number of subjects: 100
Study: 31585579

Group type: EXPERIMENTAL
Intervention: Supervised moderate to vigorous exercise (70 to 78 sessions over 24 weeks, 3 times per week, 60-65 minutes per session)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Supervised moderate to vigorous exercise
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 345
Study: 28467869

Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg twice daily)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice daily)
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1732
Study: 26449871

Group type: EXPERIMENTAL
Intervention: IP-OP suction (10 Fr suction catheter, negative pressure of 100 mmHg)
Number of subjects: 509

Group type: COMPARATOR
Intervention: No IP-OP suction (control group)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: IP-OP suction
Number of subjects: 509

Group type: COMPARATOR
Intervention: No IP-OP suction
Number of subjects: 509
Study: 24655978

Group type: EXPERIMENTAL
Intervention: EVL plus atorvastatin 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: EVL
Number of subjects: 20